- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04262739
MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors
October 19, 2020 updated by: Haim Bio Co., Ltd.
Open-label, Phase I Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors Who Have Failed Approved Standard Therapies
The objectives of this study are:
Part 1:
- To assess the MTD, safety and efficacy of each NYH817G and NYH100P in monotherapy in patients with advanced solid tumors who have failed approved standard therapies.
- To assess the PK properties and the preliminary effectiveness of monotherapy of NYH817G and NYH100P.
Part 2:
- To assess the MTD, RP2D, safety and efficacy of NYH817G and NYH100P in combination therapy in patients with advanced solid tumors who have failed approved standard therapies
- To assess the PK properties, the preliminary effectiveness and the changes in metabolism of combination therapy of NYH817G and NYH100P.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
42
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Minghua Huang
- Phone Number: +82-2-577-1373
- Email: haim@haimbio.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 19+ years old
- Diagnosed with advanced solid tumor histologically/cytologically
- Patient without standard therapies or who have failed approved standard therapies
- Those with a disease that is measurable and/or evaluable with the appropriate imaging examination according to RECIST v1.1
- ECOG performance status 0 to 2
- Patients with the suitable marrow, kidney, liver functions, blood coagulation and glycemic control functions
- Patients whose Life expectancy is over 12 weeks
- Patients who signed the agreement to voluntarily participate in this study
Exclusion Criteria:
- Patients who have received a major surgery, radiotherapy, chemotherapy, biologic therapy, targeted therapy, cancer immunotherapy or metabolic therapy within specified weeks counting from the initial administration of the IPs
- Diagnosed with a malignant tumor other than the relevant disease in the last 5 years from the initial administration of the IPs
- Toxicity level has not been recovered to CTCAE Grade 1 or lower
- Has uncontrolled metastasis to the CNS
- Suspected of having a serious infectious disease, paralysis of intestine, bowel obstruction, interstitial pneumonia or pulmonary fibrosis
- Had serious GI bleed or a disease that may affect the absorption of the oral drug in the past 4 weeks
- Considered as having a serious heart disease by the investigator or a serious internal disease
- Has administered a drug from another study within 4 weeks
- Has administered live vaccines within 4 weeks
- Has abused substance or alcohol within 12 weeks
- Has a serious trauma
- Has a history or currently has a type 1 or 2 diabetes
- Has a history of lactic acidosis
- Has glucose-6-phosphate dehydrogenase deficiency
- Has HIV or active or an active hepatitis B or C
- Has a history of psychological condition that could threaten observation of this protocol
- Has a history of hypersensitive reaction to the main ingredient or component of the IP or biguanide class drugs
- Being pregnant or a lactating woman, or (+) pregnancy test
- A female subject of a childbearing age who plans to get pregnant or disagrees to use recommended contraceptions
- Has not agreed to abstain from alcohol
- Considered as unsuitable for the study for other reason by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NYH817G
|
Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
|
Experimental: NYH100P
|
Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
|
Experimental: NYH817G and NYH100P
|
Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety assessment: Adverse event
Time Frame: Up to 2 years
|
Number of adverse events as assessed by NCI CTCAE v5.0
|
Up to 2 years
|
Effectiveness assessment: Disease control rate
Time Frame: Up to 2 years
|
To assess the clinical efficacy associated wtih the administration of NYH817G and NYH100P according to the RECIST v1.1
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) Parameter: Cmax of NYH817G and NYH100P
Time Frame: At the start and end of Cycle 1 (each cycle is 21 days)
|
Cmax is defined as the maximum observed concentration of each drug
|
At the start and end of Cycle 1 (each cycle is 21 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolite change-related: ALDH (for Part 2)
Time Frame: At the start and end of Cycle 1 (each cycle is 21 days)
|
To evaluate activity of metabolism in tumor tissues
|
At the start and end of Cycle 1 (each cycle is 21 days)
|
Metabolism imaging marker-related (for Part 2)
Time Frame: At the start and end of Cycle 1 (each cycle is 21 days)
|
FDG PET-CT (Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography)
|
At the start and end of Cycle 1 (each cycle is 21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Minkyu Jung., MD.,Ph.D., Div. of Medical Oncology. Yonsei Cancer Center.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 18, 2019
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
February 2, 2020
First Submitted That Met QC Criteria
February 7, 2020
First Posted (Actual)
February 10, 2020
Study Record Updates
Last Update Posted (Actual)
October 20, 2020
Last Update Submitted That Met QC Criteria
October 19, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBCR-GP-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia